Amino pyrimidine anticancer compounds

A pharmaceutical composition comprising a compound having the Formula 1a:

• wherein:
• X1 and X2 are independently —(CR7R8)0-1—;
• A is CH or N;
• R1 is halogen, —CF3, or —CCH;
• R2 is —P(O)R9R10;
• R3 is —S(O)2R11, —S(O)2NR11R12, —C(O)NR11R12, C(O)OR11;
• —NR11S(O)2R12, or —NR11R12;
• R4 is -x-y-z, wherein:
• x is 4-6cyclic;
• y is absent or 4-6heterocyclic;
• and z is absent or C1-3alkyl optionally substituted by 1-2 hydroxy or C1-6alkoxy groups, or z is hydroxy or —C(O)O—C0-3alkyl;
• or
• -x-y-z is C0-6alkoxy, C2-6alkenyl, C2-6alkynyl, or C0-6alkyl, each optionally substituted by 1-2 hydroxy groups;
• R5 is C0-2alkyl optionally substituted by 1-3 independent hydroxy or halogen groups;
• R6 is halo, —C0-3alkoxy, —C0-3alkyl optionally substituted by halo, or —OCF3;
• each R7 and R8 is independently H or —CH3;
• R9 and R10 are independently hydroxy, C1-6alkoxy, or C0-6alkyl, any of which can be taken together at any of their atoms to form a ring, or aryl, —O-aryl, or 4-6heterocyclic, wherein any of the foregoing can be further substituted by 3-6cyclic;
• R11 and R12 are independently C0-6alkyl, which can be taken together at any of their atoms to form a ring containing 1-3 heteroatoms;
• R11 or R12 can independently be taken at any of their atoms with the ring to which R3 is attached to form a ring;
• or a pharmaceutically acceptable salt thereof;
• which is formulated with at least one pharmaceutically acceptable carrier.